MRTX News and Press, Mirati Therapeutics Inc. From 01/14/22

Shares of oncology-focused biotech Mirati Therapeutics (NASDAQ: MRTX) have stumbled across the past few days, with the stock trading in the red by nearly 11% week to date as of Thursday's close. A spot of good news from a product that rivals its key pipeline drug seemed to be the fo...

Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group –  Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel artificial intelligence (AI) framework ...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO , Nov. 23, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside ch...

Check Out These 4 Trending Biotech Stocks Right Now Biotech stocks have been among the most exciting stocks to invest in the stock market . The reason being, this is a high-risk, high-reward industry that could appeal to a certain group of investors. The stock movement within th...

Clinical Collaboration to Support the Combination of KRAS G12C Inhibitor Adagrasib with RAF/MEK Inhibitor VS-6766 to Establish Triple Blockade of the RAS Signaling Pathway Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem On...

Mirati Therapeutics (NASDAQ:MRTX) has submitted an Investigational New Drug (IND) application to the FDA to evaluate its synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers. The Phase 1/2 clinical development strategy for MR...

Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers PR Newswire SAN DIEGO , Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a c...